Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HSK46575 tablets in combination with antitumor therapy for metastatic castration-resistant prostate cancer
CTR20260988Phase 2Active
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HSK46575 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Apr 2026; status: active.
02
Drugs
HSK46575
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20260988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260988.